JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

IQVIA Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

217.93 0.28

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

208.63

Max

221.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

17M

266M

Pardavimai

188M

4B

P/E

Sektoriaus vid.

29.657

37.461

Pelno marža

6.622

Darbuotojai

90,000

EBITDA

28M

781M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+2.1% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.5B

36B

Ankstesnė atidarymo kaina

217.65

Ankstesnė uždarymo kaina

217.93

Naujienos nuotaikos

By Acuity

34%

66%

97 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

IQVIA Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-28 23:50; UTC

Karštos akcijos

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025-10-28 23:25; UTC

Uždarbis

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025-10-28 23:18; UTC

Uždarbis

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025-10-28 22:20; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025-10-28 22:13; UTC

Uždarbis

Wal-Mart de Mexico Net Profit Falls in 3Q

2025-10-28 21:38; UTC

Uždarbis

Correction to Visa Sales Jump Article

2025-10-28 21:17; UTC

Uždarbis

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025-10-28 21:07; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- Update

2025-10-28 21:02; UTC

Uždarbis

Mondelez Tempers Outlook as Costs Rise

2025-10-28 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025-10-28 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025-10-28 23:02; UTC

Uždarbis

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025-10-28 23:01; UTC

Uždarbis

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025-10-28 22:46; UTC

Uždarbis

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025-10-28 22:45; UTC

Uždarbis

SK Hynix 3Q Net KRW12.6T >000660.SE

2025-10-28 22:44; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025-10-28 22:43; UTC

Uždarbis

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025-10-28 22:42; UTC

Uždarbis

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025-10-28 22:20; UTC

Uždarbis

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025-10-28 22:02; UTC

Uždarbis

Review & Preview: Earnings Extravaganza -- Barrons.com

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025-10-28 21:20; UTC

Uždarbis

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025-10-28 21:19; UTC

Uždarbis

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025-10-28 21:18; UTC

Uždarbis

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Akcijų palyginimas

Kainos pokytis

IQVIA Holdings Inc Prognozė

Kainos tikslas

By TipRanks

2.1% į viršų

12 mėnesių prognozė

Vidutinis 222 USD  2.1%

Aukščiausias 240 USD

Žemiausias 200 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines IQVIA Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

10

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

150.68 / 153.45Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

97 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat